TNER: A Novel Bayesian Background Error Suppression Method for Mutation Detection in Circulating Tumor DNA
暂无分享,去创建一个
Tao Xie | J. Bienkowska | Shibing Deng | P. Rejto | J. Hardwick | Kai Wang | Stephen A. Huang | Maruja Lira | Crystal Valdez | Jennifer Kinong | T. Xie
[1] Hyun-Tae Shin,et al. Characterization of background noise in capture-based targeted sequencing data , 2017, Genome Biology.
[2] Dumitru Brinza,et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy , 2017, npj Breast Cancer.
[3] Tiziana Venesio,et al. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers , 2017, Pathobiology.
[4] Giovanni Martinelli,et al. Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data , 2016, BMC Bioinformatics.
[5] Ryan D. Morin,et al. Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies , 2016, Molecular Cancer Research.
[6] Noah C Welker,et al. Fragment Length of Circulating Tumor DNA , 2016, PLoS genetics.
[7] Ken Chen,et al. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types , 2016, BMC Genomics.
[8] Karen Page,et al. The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring , 2016, Expert review of molecular diagnostics.
[9] Ash A. Alizadeh,et al. Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.
[10] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[11] Benjamin F. Voight,et al. Nature Genetics Advance Online Publication a N a Ly S I S an Expanded Sequence Context Model Broadly Explains Variability in Polymorphism Levels across the Human Genome , 2022 .
[12] Matthew W. Snyder,et al. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.
[13] Andrew E. Teschendorff,et al. An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer , 2015, Genome Biology.
[14] M. Stratton,et al. High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.
[15] Fan Zhang,et al. RVD2: an ultra-sensitive variant detection model for low-depth heterogeneous next-generation sequencing data , 2015, Bioinform..
[16] V. Wong,et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients , 2015, Proceedings of the National Academy of Sciences.
[17] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[18] Franck Molina,et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.
[19] Peter J. Campbell,et al. Subclonal variant calling with multiple samples and prior knowledge , 2014, Bioinform..
[20] Ash A. Alizadeh,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.
[21] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[22] F. Nicolantonio,et al. Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.
[23] M. Lippman,et al. Circulating tumor DNA--ready for prime time? , 2013, The New England journal of medicine.
[24] Mary Kathryn Cowles,et al. Applied Bayesian Statistics: With R and OpenBUGS Examples , 2013 .
[25] Mary Kathryn Cowles,et al. Applied Bayesian Statistics , 2013 .
[26] C. Klein,et al. Sequence error storms and the landscape of mutations in cancer , 2012, Proceedings of the National Academy of Sciences.
[27] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[28] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[29] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[30] K. Kinzler,et al. Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.
[31] Margaret C. Linak,et al. Sequence-specific error profile of Illumina sequencers , 2011, Nucleic acids research.
[32] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[33] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[34] Albert D. Shieh,et al. Statistical Applications in Genetics and Molecular Biology , 2010 .
[35] Andrew Gelman,et al. Why We (Usually) Don't Have to Worry About Multiple Comparisons , 2009, 0907.2478.
[36] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.
[37] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .